Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series

Title: Hemoadsorption as a Supportive Strategy for Severe Toxicity Associated With Chimeric Antigen Receptor T-Cell Therapy: A Case Series
Authors: Esposito, Pasquale; Gambella, Massimiliano; Russo, Elisa; Raiola, Anna Maria; Beltrametti, Elena; Conti, Novella; Porcile, Elisa; Bianzina, Stefania; Centanaro, Monica; Viazzi, Francesca; Angelucci, Emanuele
Contributors: Esposito, Pasquale; Gambella, Massimiliano; Russo, Elisa; Raiola, Anna Maria; Beltrametti, Elena; Conti, Novella; Porcile, Elisa; Bianzina, Stefania; Centanaro, Monica; Viazzi, Francesca; Angelucci, Emanuele
Publisher Information: Elsevier Inc.; RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
Publication Year: 2025
Collection: Università degli Studi di Genova: CINECA IRIS
Subject Terms: B-cell lymphoma; CAR-T therapy; blood purification; cytokine release syndrome; hemoadsorption; interleukin-6
Description: Rationale & Objective: To describe the use and effects of extracorporeal blood purification with hemoadsorption in managing severe complications after treatment with chimeric antigen receptor T-cells (CAR-T). Study Design: Retrospective analysis of a case series. Setting & Participants: Hematological department and intensive care unit from a single institution. Patients with hematological cancer who underwent CAR-T therapy between 2021 and 2023, developed severe toxicity, and were treated with hemoadsorption based on clinical indications. Results: Of 48 patients, extracorporeal blood purification was prescribed to 4 (8.3%): 3 with diffuse large B-cell lymphoma and 1 with mantle cell lymphoma. These patients experienced rapid increases in serum interleukin-6 and ferritin levels after CAR-T infusion, which progressed to severe cytokine release syndrome with hemodynamic instability and multiple-organ toxicity. Despite corticosteroid and anakinra rescue therapy after tocilizumab failure, extracorporeal blood purification with hemoadsorption was initiated at a mean of 5.2 ± 1.7 days following CAR-T infusion due to rapid clinical deterioration. The treatment was performed using continuous venovenous hemodiafiltration with an AN69ST hemofilter and a CytoSorb cartridge. One patient died 1 day after the initiation of blood purification because of concomitant cardiomyopathy progressing to multiple-organ failure. In the 3 surviving patients, interleukin-6 levels significantly decreased (from −18% to −95%), cytokine release syndrome resolved, and vasoactive support was reduced. Treatment-related complications were not observed. Limitations: Small sample size, retrospective design, and lack of a predefined hemoadsorption therapy protocol. Conclusions: A strategy based on hemoadsorption was safe and effective in mitigating inflammation and improving hemodynamics in patients with hematological cancer treated with CAR-T therapy who developed early severe toxicity. Plain Language Summary: Chimeric antigen receptor T-cell ...
Document Type: article in journal/newspaper
File Description: ELETTRONICO
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/40510619; info:eu-repo/semantics/altIdentifier/wos/WOS:001500941100007; volume:7; issue:6; firstpage:1; lastpage:6; numberofpages:6; journal:KIDNEY MEDICINE; https://hdl.handle.net/11567/1258038
DOI: 10.1016/j.xkme.2025.101001
Availability: https://hdl.handle.net/11567/1258038; https://doi.org/10.1016/j.xkme.2025.101001
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.9102A5E4
Database: BASE